12/12
02:10 am
bz
Kanzhun Ltd (BZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and User Expansion ... [Yahoo! Finance]
Low
Report
Kanzhun Ltd (BZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and User Expansion ... [Yahoo! Finance]
12/11
05:55 am
bz
KANZHUN LIMITED Announces Third Quarter 2024 Financial Results
Low
Report
KANZHUN LIMITED Announces Third Quarter 2024 Financial Results
12/9
09:09 am
bz
Kanzhun Limited (NASDAQ: BZ) had its price target raised by analysts at Barclays PLC from $14.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
Kanzhun Limited (NASDAQ: BZ) had its price target raised by analysts at Barclays PLC from $14.00 to $16.00. They now have an "overweight" rating on the stock.
12/9
07:49 am
bz
Kanzhun Limited (NASDAQ: BZ) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $15.00 price target on the stock.
Low
Report
Kanzhun Limited (NASDAQ: BZ) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $15.00 price target on the stock.
11/29
11:31 am
bz
Kanzhun Limited (NASDAQ: BZ) had its price target lowered by analysts at Citigroup Inc. from $17.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Kanzhun Limited (NASDAQ: BZ) had its price target lowered by analysts at Citigroup Inc. from $17.00 to $16.00. They now have a "buy" rating on the stock.
11/29
03:30 am
bz
KANZHUN LIMITED to Report Third Quarter 2024 Results on December 11, 2024
Medium
Report
KANZHUN LIMITED to Report Third Quarter 2024 Results on December 11, 2024
11/28
11:00 am
bz
KANZHUN LIMITED Continues Share Repurchase Program, Buying Back RMB1.4 Billion Worth of Ordinary Shares
Medium
Report
KANZHUN LIMITED Continues Share Repurchase Program, Buying Back RMB1.4 Billion Worth of Ordinary Shares
11/28
08:06 am
bz
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
Medium
Report
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
11/18
08:50 am
bz
Kanzhun Limited (NASDAQ: BZ) is now covered by analysts at CLSA. They set an "outperform" rating and a $18.00 price target on the stock.
Low
Report
Kanzhun Limited (NASDAQ: BZ) is now covered by analysts at CLSA. They set an "outperform" rating and a $18.00 price target on the stock.